Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus Insulin in Recent-Onset Type 1 Diabetes
NCT07041268Phase 2Recruiting
- Sponsor
- Pirogov Russian National Research Medical University
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Pirogov Russian National Research Medical University. Primary endpoint: Change in the Mean C-peptide Area Under Curve (AUC) Standardized by Duration of the Mixed Meal Tolerance Test at Day 365. Started Apr 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07041268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041268.